Sexually Transmitted Diseases · 2008 · 25 citations · 30 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyWomen's HealthWomen's Health PharmacotherapySexually Transmitted Infection PharmacotherapySexually Transmitted Infection PreventionSexually Transmitted InfectionsVaginal Dosage FormsVaginal Drug DeliveryDose TolerabilityHuman Immunodeficiency Virus TransmissionIntravaginal TherapyProduct Safety ProfileSerious Adverse EventsVaginal MicrobicidesVaginal OintmentsVaginal Pharmacokinetics
OBJECTIVES: This safety study of terameprocol (also called M4N, EM-1421) daily vaginal application in healthy women explores its potential application as a microbicide in interrupting human immunodeficiency virus sexual transmission and additional interruption of human papillomavirus and herpes simplex virus transmission. METHODS: A double-blind placebo controlled phase I repeat dose tolerability and pharmacokinetic, crossover study of 90 mg terameprocol (2% w/w ointment) administered intravaginally for 7 consecutive days in healthy female subjects. The pharmacokinetics after administration was examined on days 1 and 7 of dosing. Subjects underwent vaginal examination following the 6-hour pharmacokinetic sample on day 7 of each study period. RESULTS: Recruitment started January 2006 and ended May 2006, and 14 subjects completed the study. Median age was 24 years. No treatment-related serious adverse events were reported, and there were a total of 17 treatment-emergent adverse events (AE) reported by 11 participants. The most common AE was headache. Terameprocol was not detectable in serum in pharmacokinetic samples. CONCLUSIONS: Terameprocol was well tolerated at a 90 mg dose (2% wt/wt) administered vaginally daily for 7 days. No serious adverse events occurred and any AEs were mild. The excellent safety profile supports future clinical trial to evaluate the application of intravaginal terameprocol in women.
30
Prevalence of HPV Infection Among Females in the United States
Eileen F. Dunne, Elizabeth R. Unger, Maya Sternberg et al. · JAMA · 2007 · 1.6K citations · Full text
James E. Cummins, Jeannette Guarner, Lisa Flowers et al. · Antimicrobial Agents and Chemotherapy · 2007 · 140 citations · Full text